Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
NCT00111462 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2013-05-08
Summary
The purpose of this study is to compare the effect of darbepoetin alfa administered in a weight based versus fixed dosing for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.
Conditions
Interventions
- DRUG
-
Darbepoetin alfa
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- FACTORIAL
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
NCT00091858 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
NCT00111137 ·Status: COMPLETED ·Phase: PHASE3
-
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
NCT03776032 ·Status: COMPLETED ·Phase: PHASE3
-
Darbepoetin Alfa and Anemia of Cancer
NCT00989092 ·Status: TERMINATED ·Phase: PHASE2
-
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
NCT00148421 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
NCT00115167 ·Status: COMPLETED ·Phase: PHASE3
-
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
NCT00239239 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
NCT00120705 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
NCT00540696 ·Status: COMPLETED ·Phase: PHASE2
-
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
NCT00095277 ·Status: COMPLETED ·Phase: PHASE2
-
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
NCT00858364 ·Status: TERMINATED ·Phase: PHASE3
-
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
NCT00070382 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy
NCT00540384 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
NCT00036023 ·Status: COMPLETED ·Phase: PHASE2
-
Darbepoetin Alfa With or Without Intravenous (IV) Iron
NCT00401544 ·Status: COMPLETED ·Phase: PHASE2
-
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
NCT00153868 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment for Patients Suffering From Anemia Due to Chemotherapy
NCT00120692 ·Status: COMPLETED ·Phase: PHASE2
-
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
NCT00661999 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
NCT00117117 ·Status: COMPLETED ·Phase: PHASE4
-
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
NCT00144131 ·Status: COMPLETED ·Phase: PHASE2
-
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
NCT00416624 ·Status: COMPLETED ·Phase: PHASE2
-
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
NCT00135317 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy
NCT00120679 ·Status: COMPLETED ·Phase: PHASE2
-
Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia
NCT00212862 ·Status: COMPLETED
-
A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
NCT00119600 ·Status: TERMINATED ·Phase: PHASE1/PHASE2